June 27, 2008 - Schering-Plough Corp. (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK) announce the withdrawal of the New Drug Application (NDA) for the loratadine/montelukast combination tablet.The companies also terminated the Schering-Plough/Merck Pharmaceuticals respiratory joint venture, which was formed in May 2000 to develop and market a fixed-combination product that would combine loratadine and montelukast.
This action has no impact on the business of the Merck/Schering-Plough cholesterol joint venture... Merck's Press Release - Schering-Plough's Press Release -
